51
|
Koh J, Hur J, Lee K, Kim M, Heo J, Ku B, Sun J, Lee S, Ahn J, Park K, Ahn M. P60.09 High Circulating Regulatory (FoxP3+) T Cells and TGF-β Predict the Response to Anti-PD-1 Immunotherapy in NSCLC Patients. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
52
|
Goto K, Wolf J, Elamin Y, Santini F, Soldatenkova V, Sashegyi A, Lin AB, Lin B, Novello S, Arriola Aperribay E, Perol M, Loong H, Drilon A, Park K, Solomon B, Zhou C. FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.148] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
53
|
Veillon R, Sakai H, Le X, Felip E, Garassino M, Cortot A, Smit E, Park K, Griesinger F, Britschgi C, Wu Y, Berghoff K, Otto G, Bruns R, Paik P. FP14.09 Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
54
|
Paik P, Sakai H, Felip E, Veillon R, Garassino M, Raskin J, Viteri S, Mazieres J, Cortot A, Smit E, Thomas M, Cho B, Conte P, Yang J, Morise M, Chen Y, Park K, Gottfried M, Britschgi C, Bruns R, Otto G, Johne A, Le X. MA11.05 Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
55
|
Cho B, Kim D, Laurie S, Mckeage M, Borra G, Park K, Kim S, Ghosn M, Ardizzoni A, Greystoke A, Izquierdo M, Wang Y, Wang L, Wrona A. P84.05 Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1204] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
56
|
Lee J, Choi Y, Han J, Park S, Jung H, Sun J, Lee S, Ahn J, Park K, Ahn M. P76.15 Osimertinib Improved Overall Survival in mEGFR NSCLC Patients With Leptomeningeal Metastases Regardless of T790M Mutational Status. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
57
|
Boyer M, Sendur M, Rodríguez-Abreu D, Park K, Lee D, Cicin I, Yumuk P, Orlandi F, Leal T, Molinier O, Soparattanapaisam N, Langleben A, Califano R, Medgyasszay B, Hsia T, Otterson G, Xu L, Piperdi B, Samkari A, Reck M. PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.322] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
58
|
Mirazita M, Avakian H, Courtoy A, Pisano S, Adhikari S, Amaryan MJ, Angelini G, Atac H, Baltzell NA, Barion L, Battaglieri M, Bedlinskiy I, Benmokhtar F, Bianconi A, Biselli AS, Bossù F, Boiarinov S, Briscoe WJ, Brooks WK, Bulumulla D, Burkert VD, Carman DS, Carvajal JC, Celentano A, Chatagnon P, Chetry T, Ciullo G, Clary B, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Dashyan N, De Vita R, Defurne M, Deur A, Diehl S, Dilks C, Djalali C, Dupre R, Egiyan H, Ehrhart M, Alaoui AE, Fassi LE, Eugenio P, Fegan S, Fersch R, Filippi A, Forest TA, Ghandilyan Y, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Glazier DI, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guo L, Hafidi K, Hakobyan H, Hattawy M, Hayward TB, Heddle D, Hicks K, Hobart A, Holtrop M, Huang Q, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Joo K, Keller D, Khanal A, Khandaker M, Kim CW, Kim W, Klein FJ, Kubarovsky V, Kuhn SE, Lanza L, Leali M, Lenisa P, Livingston K, MacGregor IJD, Marchand D, Markov N, Marsicano L, Mascagna V, McKinnon B, Milner RG, Mineeva T, Mokeev V, Mullen C, Camacho CM, Neupane K, Niculescu G, O'Connell T, Osipenko M, Paolone M, Pappalardo LL, Paremuzyan R, Park K, Pasyuk E, Phelps W, Pocanic D, Pogorelko O, Poudel J, Prok Y, Raue BA, Ripani M, Ritman J, Rizzo A, Rossi P, Sabatié F, Salgado C, Schmidt A, Schumacher RA, Sharabian YG, Shrestha U, Soto O, Sparveris N, Stepanyan S, Strakovsky II, Strauch S, Tyler N, Ungaro M, Venturelli L, Voskanyan H, Vossen A, Voutier E, Watts D, Wei K, Wei X, Wood MH, Yale B, Zachariou N, Zhang J, Zhao ZW. Beam Spin Asymmetry in Semi-Inclusive Electroproduction of Hadron Pairs. PHYSICAL REVIEW LETTERS 2021; 126:062002. [PMID: 33635681 DOI: 10.1103/physrevlett.126.062002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/23/2020] [Accepted: 01/12/2021] [Indexed: 06/12/2023]
Abstract
A first measurement of the longitudinal beam spin asymmetry A_{LU} in the semi-inclusive electroproduction of pairs of charged pions is reported. A_{LU} is a higher-twist observable and offers the cleanest access to the nucleon twist-3 parton distribution function e(x). Data have been collected in the Hall-B at Jefferson Lab by impinging a 5.498-GeV electron beam on a liquid-hydrogen target, and reconstructing the scattered electron and the pion pair with the CLAS detector. One-dimensional projections of the A_{LU}^{sinϕ_{R}} moments are extracted for the kinematic variables of interest in the valence quark region. The understanding of dihadron production is essential for the interpretation of observables in single-hadron production in semi-inclusive DIS, and pioneering measurements of single-spin asymmetries in dihadron production open a new avenue in studies of QCD dynamics.
Collapse
|
59
|
Meyer JM, Lee E, Celli A, Park K, Cho R, Lambert W, Pitchford M, Gordon M, Tsai K, Cleaver J, Arron ST, Mauro TM. CERKL is upregulated in cutaneous squamous cell carcinoma and maintains cellular sphingolipids and resistance to oxidative stress. Br J Dermatol 2021; 185:147-152. [PMID: 33393080 DOI: 10.1111/bjd.19753] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/30/2020] [Indexed: 01/16/2023]
Abstract
BACKGROUND Ceramide kinase-like protein (CERKL) was originally described in retinal tissue. CERKL has been shown to protect cells from oxidative stress, and mutations in CERKL underlie the inherited disease retinitis pigmentosa. CERKL expression maintains cellular sphingolipids via an unknown mechanism. OBJECTIVES To determine whether CERKL is expressed in epidermis and cutaneous squamous cell carcinoma (cSCC) and whether CERKL expression affects cSCC sphingolipid metabolism and susceptibility to oxidative stress. METHODS CERKL expression was determined by RNA-Seq, quantitative polymerase chain reaction and immunohistochemistry. CERKL was knocked down in cSCC cells using small interfering RNA. Sphingolipid content was analysed by liquid chromatography-mass spectrometry. Oxidative stress was induced by treatment with H2 O2 , and apoptosis was measured using flow cytometry to determine annexin V binding. RESULTS CERKL mRNA and protein are highly expressed in actinic keratosis and cSCC in comparison with normal epidermis. CERKL is also expressed in metabolically active epithelial cells in normal hair bulbs and sebaceous glands. CERKL knockdown in cultured cSCC cells reduces cellular sphingolipid content and enhances susceptibility to oxidative stress. CONCLUSIONS These findings suggest that CERKL may be important in cSCC progression and could lead to novel strategies for prevention and treatment of cSCC.
Collapse
|
60
|
Karthik R, Pandiselvi K, Mariyappan K, Park K, Kwak IS, Sivakamavalli J. Synthesis of Biogenic Chitosan Biopolymer-Functionalized Zinc-Doped Bi2O3 Nanoneedles and Its Bio-applications: In Vitro Antibacterial and Anticancer activity. ARABIAN JOURNAL FOR SCIENCE AND ENGINEERING 2021. [DOI: 10.1007/s13369-020-05099-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
61
|
Hong D, Bang YJ, Barlesi F, Durm G, Falchook G, Govindan R, Dy G, Park K, Strickler J, Burns T, Kim J, Ang A, Lipford J, Ngarmchamnanrith G, Anderson A, Li B. MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.136] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
62
|
Chih-Hsin Yang J, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. MO01.36 Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm+) NSCLC Harboring Major Uncommon Mutations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
63
|
Fuchs M, Almeyda CV, Al Rwahnih M, Atallah SS, Cieniewicz EJ, Farrar K, Foote WR, Golino DA, Gómez MI, Harper SJ, Kelly MK, Martin RR, Martinson T, Osman FM, Park K, Scharlau V, Smith R, Tzanetakis IE, Vidalakis G, Welliver R. Economic Studies Reinforce Efforts to Safeguard Specialty Crops in the United States. PLANT DISEASE 2021; 105:14-26. [PMID: 32840434 DOI: 10.1094/pdis-05-20-1061-fe] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Pathogen-tested foundation plant stocks are the cornerstone of sustainable specialty crop production. They provide the propagative units that are used to produce clean planting materials, which are essential as the first-line management option of diseases caused by graft-transmissible pathogens such as viruses, viroids, bacteria, and phytoplasmas. In the United States, efforts to produce, maintain, and distribute pathogen-tested propagative material of specialty crops are spearheaded by centers of the National Clean Plant Network (NCPN). Agricultural economists collaborated with plant pathologists, extension educators, specialty crop growers, and regulators to investigate the impacts of select diseases caused by graft-transmissible pathogens and to estimate the return on investments in NCPN centers. Economic studies have proven valuable to the NCPN in (i) incentivizing the use of clean planting material derived from pathogen-tested foundation plant stocks; (ii) documenting benefits of clean plant centers, which can outweigh operating costs by 10:1 to 150:1; (iii) aiding the development of disease management solutions that are not only ecologically driven but also profit maximizing; and (iv) disseminating integrated disease management recommendations that resonate with growers. Together, economic studies have reinforced efforts to safeguard specialty crops in the United States through the production and use of clean planting material.
Collapse
|
64
|
Shahamatifard F, Rodrigue D, Park K, Frikha S, Mighri F. Preparation and Characterization of Reduced Graphene Oxide Based Natural Rubber Nanocomposites. INT POLYM PROC 2020. [DOI: 10.1515/ipp-2020-350511] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
This work describes the effect of reduced graphene oxide (RGO) addition in natural rubber (NR). Firstly, RGO was synthesized based on the improved Hummer’s method then characterized by Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), and thermogravimetric analysis (TGA) to confirm that the RGO surface contains hydroxyl, epoxy, and carboxyl functional groups to improve graphene interaction with the NR matrix. In a second step, the synthesized RGO was predispersed in NR latex using the co-coagulation technique then added at different amounts (0 to 2 parts per hundred rubber (phr)) to a basic NR formulation and compounded in an internal mixer. The results show that the crosslink density of the developed NR/RGO nanocomposites increased by 65% for RGO concentration of 2.0 phr. For the same RGO concentration, a significant increase in tensile strength (53%) and Young’s modulus (31%) were also observed. Finally, a significant improvement (26%) of the thermal conductivity was obtained with the addition of only 0.5 phr of RGO.
Collapse
|
65
|
Meyer JM, Lee E, Celli A, Park K, Cho R, Lambert W, Pitchford M, Gordon M, Tsai K, Cleaver J, Arron ST, Mauro TM. CERKL is Upregulated in Cutaneous Squamous Cell Carcinoma and Maintains Cellular Sphingolipids and Resistance to Oxidative Stress. Br J Dermatol 2020:10.1111/bjd.19707. [PMID: 33270220 PMCID: PMC8172666 DOI: 10.1111/bjd.19707] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Ceramide Kinase-Like Protein (CERKL) was originally described in retinal tissue. CERKL has been shown to protect cells from oxidative stress, and mutations in CERKL underlie the inherited disease, retinitis pigmentosa. CERKL expression maintains cellular sphingolipids via an unknown mechanism. OBJECTIVES To determine whether CERKL is expressed in epidermis and cutaneous squamous cell carcinoma (cSCC) and whether CERKL expression affects cSCC sphingolipid metabolism and susceptibility to oxidative stress. METHODS CERKL expression was determined by RNA-Seq, qPCR and immunohistochemistry. CERKL was knocked down in cSCC cells using siRNA. Sphingolipid content was analyzed by liquid chromatography-mass spectrometry (LC-MS). Oxidative stress was induced by treatment with H2 O2 , and apoptosis was measured using flow cytometry to determine annexin v binding. RESULTS CERKL mRNA and protein are highly expressed in actinic keratosis and cSCC in comparison with normal epidermis. CERKL also is expressed in metabolically active epithelial cells in normal hair bulbs and sebaceous glands. CERKL knockdown in cultured cSCC cells reduces cellular sphingolipid content and enhances susceptibility to oxidative stress. CONCLUSIONS These findings suggest that CERKL may be important in cSCC progression and could lead to novel strategies for prevention and treatment of cSCC.
Collapse
|
66
|
Shahamatifard F, Rodrigue D, Park K, Frikha S, Mighri F. Preparation and Characterization of Reduced Graphene Oxide Based Natural Rubber Nanocomposites. INT POLYM PROC 2020. [DOI: 10.3139/217.3987] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
67
|
Cho B, Loong H, Tsai CM, Teo M, Park K, Kim H, Lee M, Olsen S. 308P The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
68
|
Yang JH, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. 395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
69
|
Diehl S, Joo K, Kim A, Avakian H, Kroll P, Park K, Riser D, Semenov-Tian-Shansky K, Tezgin K, Adhikari KP, Adhikari S, Amaryan MJ, Angelini G, Asryan G, Atac H, Barion L, Battaglieri M, Bedlinskiy I, Benmokhtar F, Bianconi A, Biselli AS, Bossù F, Boiarinov S, Briscoe WJ, Brooks WK, Bulumulla D, Burkert VD, Carman DS, Carvajal JC, Celentano A, Chatagnon P, Chetry T, Ciullo G, Clark L, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Dashyan N, De Vita R, Defurne M, Deur A, Dilks C, Djalali C, Dupre R, Egiyan H, Ehrhart M, El Alaoui A, El Fassi L, Eugenio P, Filippi A, Forest TA, Ghandilyan Y, Gilfoyle GP, Giovanetti KL, Girod FX, Glazier DI, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guo L, Hakobyan H, Harrison N, Hattawy M, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Joosten S, Keller D, Khachatryan M, Khanal A, Khandaker M, Kim CW, Kim W, Kubarovsky V, Kuhn SE, Lanza L, Leali M, Lenisa P, Livingston K, MacGregor IJD, Marchand D, Markov N, Marsicano L, Mascagna V, McKinnon B, Meziani ZE, Mineeva T, Mirazita M, Mokeev V, Munoz Camacho C, Nadel-Turonski P, Niculescu G, Osipenko M, Paolone M, Pappalardo LL, Pasyuk E, Phelps W, Pogorelko O, Price JW, Prok Y, Raue BA, Ripani M, Rizzo A, Rossi P, Rowley J, Sabatié F, Salgado C, Schmidt A, Schumacher RA, Sharabian YG, Shrestha U, Soto O, Sparveris N, Stepanyan S, Stoler P, Strakovsky II, Strauch S, Tan JA, Tyler N, Ungaro M, Venturelli L, Voskanyan H, Voutier E, Watts DP, Wei X, Wood MH, Zachariou N, Zhang J, Zhao ZW. Extraction of Beam-Spin Asymmetries from the Hard Exclusive π^{+} Channel off Protons in a Wide Range of Kinematics. PHYSICAL REVIEW LETTERS 2020; 125:182001. [PMID: 33196236 DOI: 10.1103/physrevlett.125.182001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 06/08/2020] [Accepted: 07/30/2020] [Indexed: 06/11/2023]
Abstract
We have measured beam-spin asymmetries to extract the sinϕ moment A_{LU}^{sinϕ} from the hard exclusive e[over →]p→e^{'}nπ^{+} reaction above the resonance region, for the first time with nearly full coverage from forward to backward angles in the center of mass. The A_{LU}^{sinϕ} moment has been measured up to 6.6 GeV^{2} in -t, covering the kinematic regimes of generalized parton distributions (GPD) and baryon-to-meson transition distribution amplitudes (TDA) at the same time. The experimental results in very forward kinematics demonstrate the sensitivity to chiral-odd and chiral-even GPDs. In very backward kinematics where the TDA framework is applicable, we found A_{LU}^{sinϕ} to be negative, while a sign change was observed near 90° in the center of mass. The unique results presented in this Letter will provide critical constraints to establish reaction mechanisms that can help to further develop the GPD and TDA frameworks.
Collapse
|
70
|
Kim M, Park K, Choi I. The metabolic suppressor 3-iodothyronamine enhances lipolysis in 3T3-L1 adipocytes via activation of the adenosine monophosphate-activated protein kinase/forkhead box O1 signaling pathway. JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2020; 71. [PMID: 33077693 DOI: 10.26402/jpp.2020.3.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Accepted: 06/30/2020] [Indexed: 11/03/2022]
Abstract
Obesity is a major health concern in modern societies as it is linked to diverse chronic diseases, such as diabetes, cancer, stroke, and skeletomuscular disorders. This study aimed to investigate the lipolytic potency of the metabolic suppressor 3-iodothyronamine (T1AM) and its molecular mechanism in differentiated 3T3-L1 adipocytes. Cells stained with Oil Red O showed a remarkable accumulation of lipid droplets by 20-d post-differentiation and a plateau at 26 - 30 day. Treatment with 100 μM T1AM for 6 h increased the liberation of free fatty acids (FFAs) and glycerol (P < 0.05) detected in the culture media. However, this stimulatory effect was significantly suppressed by ATGListatin, an inhibitor of adipose triglyceride lipase (ATGL), suggesting that ATGL plays a rate-limiting role in triglyceride (TG) turnover. To understand the lipolytic mechanism, immunoblotting and confocal image analyses of the T1AM-treated and control groups were conducted. The elevated lipolysis was accompanied by increases in the phosphorylation of adenosine monophosphate-activated protein kinase (p-AMPK), nuclear localization of forkhead box O1 (FoxO1), and expression of monoacylglycerol lipase (MGL) protein (P < 0.05). Finally, the treated cells exhibited downregulated expression of acetyl-CoA carboxylase (ACC) relative to p-ACC and increased protein expression of carnitine palmitoyltransferase 1 (CPT1) (P < 0.05). Taken together, T1AM showed lipolytic potency via activation of the AMPK/FoxO1/ATGL/MGL axis for decomposing TGs to FFAs and glycerol and of the AMPK/ACC/CPT1 pathway in facilitating the mobilization of FFAs into the mitochondria, highlighting its therapeutic potential for the treatment of obesity.
Collapse
|
71
|
Hong D, Bang YJ, Barlesi F, Durm G, Falchook G, Govindan R, Dy G, Park K, Strickler J, Burns T, Kim J, Ang A, Lipford J, Ngarmchamnanrith G, Anderson A, Li B. 1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1571] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
72
|
Reck M, Spira A, Besse B, Wolf J, Skoulidis F, Borghaei H, Goto K, Park K, Griesinger F, Felip E, Boyer M, Barrios C, Goss G, Yang H, Obiozor C, Ramalingam S. 1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1730] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
73
|
Yeo J, Park S, Jung H, Sun JM, Lee S, Ahn J, Park K, Ahn MJ. 1395P Who will maintain as long-term responders more than 3 years with first- or second-generation EGFR TKI among EGFR mutant NSCLC? Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
74
|
Nakagawa K, Nadal E, Garon E, Nishio M, Seto T, Yamamoto N, Park K, Shih JY, Frimodt-Moller B, Zimmermann A, Visseren-Grul C, Reck M. 1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1608] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
75
|
Kim G, Yoon S, Park K, Sohn KY, Kim MH, Kim J. 576P The synergistic anticancer effect of PLAG on the PD-1 immune checkpoint inhibitor in the LLC-1 murine lung carcinoma syngeneic model. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
76
|
Yang JH, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. 1341P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
77
|
Cabanillas M, Drilon A, Farago A, Brose M, McDermott R, Sohal D, Oh DY, Almubarak M, Bauman J, Chu E, Kummar S, Leyvraz S, Park K, Reeves J, Dima L, Maeda P, Rodrigues L, Brega N, Hong D, Waguespack S. 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1404] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
78
|
McCoach C, Tan D, Besse B, Goto K, Zhu V, Rolfo C, Farajian S, Potter L, Kherani J, Soldatenkova V, Olek E, Lee P, Park K. 1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1605] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
79
|
Cho B, Lee K, Cho E, Kim DW, Lee JS, Han JY, Kim SW, Spira A, Haura E, Sabari J, Sanborn R, Bauml J, Gomez J, Lorenzini P, Infante J, Xie J, Haddish-Berhane N, Thayu M, Knoblauch R, Park K. 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1572] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
80
|
Loong H, Goto K, Elamin Y, Solomon B, Santini F, Soldatenkova V, Sashegyi A, Lin AB, Lin B, Wolf J, Oxnard G, Zhou C, Drilon A, Park K. 1413TiP LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1727] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
81
|
Cho BC, Kim DW, Batra U, Park K, Kim SW, Yang C, Jye VP, Sriuranpong V, Babu K, Amin K, Wang Y, Wang L, Bhering M, Geater SL. 1348P Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
82
|
Park K, Kim JJ, Oh SB, Jung K, Oh S, Park EJ, Hong Y, Kim J, Jang J, Jeon UB. 1508P Safety, efficacy, and patients' satisfaction of initial peripherally inserted central catheters compared with usual intravenous access in terminally ill cancer patients: A randomized phase II study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
83
|
Kim SB, Keam B, Shin S, Chae Y, Seo S, Park K, Kim T, Park L, Hong SB, Lim E, Lee S, Ahn MJ. 928P Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
84
|
Mun GA, Moldakhan I, Serikbay AM, Kaldybekov D, Suleimenov IE, Park K. Hydrophilic interpolymer associates – the key to solving the problem of pre-biological evolution. INTERNATIONAL JOURNAL OF BIOLOGY AND CHEMISTRY 2020. [DOI: 10.26577/ijbch.2020.v13.i1.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
85
|
Larin I, Zhang Y, Gasparian A, Gan L, Miskimen R, Khandaker M, Dale D, Danagoulian S, Pasyuk E, Gao H, Ahmidouch A, Ambrozewicz P, Baturin V, Burkert V, Clinton E, Deur A, Dolgolenko A, Dutta D, Fedotov G, Feng J, Gevorkyan S, Glamazdin A, Guo L, Isupov E, Ito MM, Klein F, Kowalski S, Kubarovsky A, Kubarovsky V, Lawrence D, Lu H, Ma L, Matveev V, Morrison B, Micherdzinska A, Nakagawa I, Park K, Pedroni R, Phelps W, Protopopescu D, Rimal D, Romanov D, Salgado C, Shahinyan A, Sober D, Stepanyan S, Tarasov VV, Taylor S, Vasiliev A, Wood M, Ye L, Zihlmann B. Precision measurement of the neutral pion lifetime. Science 2020; 368:506-509. [PMID: 32355026 DOI: 10.1126/science.aay6641] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 03/30/2020] [Indexed: 11/02/2022]
Abstract
The explicit breaking of the axial symmetry by quantum fluctuations gives rise to the so-called axial anomaly. This phenomenon is solely responsible for the decay of the neutral pion π0 into two photons (γγ), leading to its unusually short lifetime. We precisely measured the decay width Γ of the [Formula: see text] process. The differential cross sections for π0 photoproduction at forward angles were measured on two targets, carbon-12 and silicon-28, yielding [Formula: see text], where stat. denotes the statistical uncertainty and syst. the systematic uncertainty. We combined the results of this and an earlier experiment to generate a weighted average of [Formula: see text] Our final result has a total uncertainty of 1.50% and confirms the prediction based on the chiral anomaly in quantum chromodynamics.
Collapse
|
86
|
Park K, Ko B, Kim D. P274 Electrode number constrained transcranial direct current stimulation optimization strategy. Clin Neurophysiol 2020. [DOI: 10.1016/j.clinph.2019.12.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
87
|
Kim C, Kim D, Hong H, Park K. Thermoelectric properties of La3+ and Ce3+ co-doped CaMnO3 prepared by tape casting. Ann Ital Chir 2020. [DOI: 10.1016/j.jeurceramsoc.2019.08.021] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
88
|
Kim R, Do Y, Park K, Park H, Kim D, Heo S. Abstract No. 682 Updates for extremity arteriovenous malformations involving the bone: approach for embolization and its therapeutic outcomes. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
89
|
Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Ann Oncol 2019; 29:1548-1553. [PMID: 29767677 DOI: 10.1093/annonc/mdy177] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an antitumor immune response. This phase III trial determined the efficacy of bavituximab combined with docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). Patients and methods Key eligibility criteria included advanced non-squamous NSCLC with disease progression after treatment with platinum-based doublet chemotherapy, evidence of disease control after at least two cycles of first-line therapy, presence of measurable disease, ECOG performance status 0 or 1, adequate bone marrow and organ function, and no recent history of clinically significant bleeding. Eligible patients were randomized 1 : 1 to receive up to six 21-day cycles of docetaxel plus either weekly bavituximab 3 mg/kg or placebo until progression or toxicity. The primary end point was overall survival (OS). Results A total of 597 patients were enrolled. Median OS was 10.5 months in the docetaxel + bavituximab arm and was 10.9 months in the docetaxel + placebo arm (HR 1.06; 95% CI 0.88-1.29; P = 0.533). There was no difference in progression-free survival (HR 1.00; 95% CI 0.82-1.22; P = 0.990). Toxicities were manageable and similar between arms. In subset analysis, among patients with high baseline serum β2GP1 levels ≥200 µg/ml, a nonsignificant OS trend favored the bavituximab arm (HR 0.82; 95% CI 0.63-1.06; P = 0.134). Among patients who received post-study immune checkpoint inhibitor therapy, OS favored the bavituximab arm (HR 0.46; 95% CI 0.26-0.81; P = 0.006). Conclusions The combination of bavituximab plus docetaxel is not superior to docetaxel in patients with previously treated advanced NSCLC. The addition of bavituximab to docetaxel does not meaningfully increase toxicity. The potential benefit of bavituximab observed in patients with high β2GP1 levels and in patients subsequently treated with immune checkpoint inhibitors requires further investigation. Clinical trial number NCT01999673.
Collapse
|
90
|
Gottfried M, de Marinis F, Tu H, Laktionov K, Feng J, Poltoratskiy A, Zhao J, Tan EH, Lee V, Kowalski D, Yang CT, Srinivasa B, Passaro A, Clementi L, Tang W, Huang DL, Cseh A, Park K, Zhou C, Wu YL. Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
91
|
Park K, Zhou J, Kim DW, Ahmad A, Soo R, Bruns R, Straub J, Johne A, Scheele J, Yang JH, Wu YL. Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
92
|
Park K, Felip E, Veillon R, Cortot A, Mazieres J, Sakai H, Reinmuth N, Viteri S, Chen YM, Han JY, Jang TW, Morise M, Sakamoto T, Tokito T, Cho B, Bruns R, Scheele J, Straub J, Le X, Paik P. Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz420.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
93
|
Oh S, Kim JJ, Oh SY, Park K. Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz434.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
94
|
Passaro A, De Marinis F, Tu H, Laktionov K, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa B, Clementi L, Tang W, Huang DL, Cseh A, Park K, Zhou C, Wu YL. Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
95
|
Ryoo H, Park K, Kim J. DEVELOPMENT OF MINI-COMPREHENSIVE GERIATRIC ASSESSMENT FOR THE ELDERLY CANCER PATIENTS BASED ON RELATIONSHIPS BETWEEN COMPREHENSIVE GERIATRIC ASSESSMENT ITEMS AND PERFORMANCE STATUS. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31243-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
96
|
Kim SB, Keam B, Shin S, Chae Y, Kim T, Kim MS, Kim J, Park K, Ahn J, Park L, Lee E, Juhn J, Kim S, Hong SB, Ahn MJ. First in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
97
|
Seong M, Park S, Jung H, Sun J, Lee S, Ahn J, Park K, Kim S, Ahn M. P1.01-97 Modified RANO-LM Criteria to Evaluate the Radiological Response of Osimertinib in EGFR T790M Positive NSCLC with Leptomeningeal Metastases. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
98
|
Jung H, Hong S, Park J, Park M, Sun J, Lee S, Ahn J, Ahn M, Park K. MA19.06 Successful Development of Realtime Automatically Updated Data Warehouse in Health Care (ROOT-S). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.659] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
99
|
Park K. P2.13-13 Should Visceral Pleural Invasion Be Prognostic Factor in Patient with Smaller Sized Adenocarcinoma? J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
100
|
Drilon A, Oxnard G, Wirth L, Besse B, Gautschi O, Tan S, Loong H, Bauer T, Kim Y, Horiike A, Park K, Shah M, McCoach C, Bazhenova L, Seto T, Brose M, Pennell N, Weiss J, Matos I, Peled N, Cho B, Ohe Y, Reckamp K, Boni V, Satouchi M, Falchook G, Akerley W, Daga H, Sakamoto T, Patel J, Lakhani N, Barlesi F, Burkard M, Zhu V, Moreno Garcia V, Medioni J, Matrana M, Rolfo C, Lee D, Nechushtan H, Johnson M, Velcheti V, Nishio M, Toyozawa R, Ohashi K, Song L, Han J, Spira A, De Braud F, Staal Rohrberg K, Takeuchi S, Sakakibara J, Waqar S, Kenmotsu H, Wilson F, B.Nair, Olek E, Kherani J, Ebata K, Zhu E, Nguyen M, Yang L, Huang X, Cruickshank S, Rothenberg S, Solomon B, Goto K, Subbiah V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.059] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|